Navigation Links
Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
Date:2/16/2017

SAN DIEGO, Feb. 16, 2017 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, today announced it has completed a $5 million Series 1a financing and entered into a $5 million credit facility with Silicon Valley Bank (SVB).  Dermata intends to use the capital for general corporate purposes to further Dermata's mission of making major advancements in the treatment of serious diseases treated by dermatologists.  

"We believe this funding strategy will provide us with the necessary capital to complete our two ongoing Phase 2 clinical studies with our lead candidate DMT210 in atopic dermatitis and rosacea. Moreover, it aligns us with a premier partner in SVB, helping us manage our cost of capital moving forward and providing the opportunity for significant value creation for our unit holders," states Gerald Proehl, President and CEO of Dermata. 

Dermata received $2.5 million at closing and, under the terms of the agreement, will receive an additional $2.5 million later this year, subject to achievement of certain specified milestones.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has an experienced team who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea.  To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.


CONTACT:

Dermata ContactSean ProehlInvestor Relations858.223.0882sproehl@dermatarx.com


 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-closes-a-5-million-series-1a-financing-and-secures-a-5-million-credit-facility-with-silicon-valley-bank-300408534.html


'/>"/>
SOURCE Dermata Therapeutics, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
5. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
6. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
7. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
8. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
11. Immunomic Therapeutics, Inc. Makes Significant Headway in Regulatory Interactions in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... RoviSys, a ... today that it has joined the Cisco® Digital Solutions Integrator Program. As a ... hardware and software that addresses Industrial IT and Business IT in manufacturing environments. ...
(Date:2/28/2017)... ... , ... Over 8,000 recognized rare diseases afflict an estimated 350 million people ... March 7, DrugDev will gather international experts to share challenges and provide insight and ... Overcoming the Challenges of Rare Disease Clinical Trials, Date: March 7, 2017, Time: 10:00-11:00 ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen Inc ... millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. , ... express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody ...
(Date:2/28/2017)... and PHILADELPHIA , Feb. 28, 2017 ... held biopharmaceutical company focusing on debilitating diseases including rare ... announced that the company joins with the National Organization ... advocacy and support around the world in commemorating Rare ... unique challenges and needs of the millions of patients ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/24/2017)... Feb. 24, 2017  EyeLock LLC, a leader of iris-based ... iris biometric solution on the latest Qualcomm® Snapdragon™ ... Mobile World Congress 2017 (February 27 – ... Hall 3, Stand 3E10. The ... security platform—a combination of hardware, software and ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):